CI Stock Price Today (September 2026) — The Cigna Group Analysis & Key Metrics 2026-09-03
The Cigna Group (CI) is trading at $286.26, up 1.21% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $341.42 (19.3% upside).
- Volatility remains elevated (17.22% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.70% YoY) alongside significant competitive pressures.
CI Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
The Cigna Group - Historical Price & Volume
Market Cap
Enterprise Value: $97.86B
P/E Ratio
Forward P/E: 8.24
Revenue Growth
Year over Year
Analyst Target
+19.3% upside potential
Key Investor Questions About CI
What investors need to know before buying
Based on current market data, CI presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 59.24)
- Fundamentals say: Caution warranted (high leverage concerns)
CI's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CI investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $31.88B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CI stock traded between $239.51 and $315.47—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 17.22% annualized volatility and β=0.20, the stock exhibits low sensitivity to market moves—making CI suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
UnitedHealth Stock Recovered Before Its Margins Did
UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.
CVS Stock Has Left Its Peers Behind. Or Has It?
The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.
The Bull Case For Cigna Group (CI) Could Change Following Its New Connected Benefits Platform Launch
Cigna Healthcare recently introduced an industry-first connected benefits experience that links medical and supplemental health coverage to simplify access to cash benefits for unexpected health events, with Medical with Smart Coverage slated to begin offering supplemental cash of up to US$7,000 per covered event from January 2027 for eligible mid-sized employer plans. This move directly addresses widespread gaps in Americans’ financial readiness for medical shocks and the underuse of...
How Is The Cigna Group’s Stock Performance Compared to Other Healthcare Plans
CI has underperformed the broader market over the past year, despite analysts remaining moderately bullish on its future prospects.
2 of Wall Street’s Favorite Stocks Worth Investigating and 1 We Turn Down
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest
Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.
UNH Stock Gets Cheaper Only If The Margins Come Back
Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.
Is CVS Stock Set for a Rebound?
Its market-shock drawdowns have been ordinary in depth, and some of its longest waits back to the old high came after falls the index barely noticed.
Can a $68 Billion Payout Save UNH Stock?
The healthcare giant sent a fortune back to its owners, but the market yawned. Here’s the real accounting of what that cash bought, and what it didn't.
Can Cigna's Smart Coverage Help Close Health-Cost Gaps?
CI's Smart Coverage links medical and supplemental benefits, offering up to $7,000 and automated claims for costly health events.
Explore More Analysis for CI
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about The Cigna Group
The Cigna Group (CI) is currently trading at $286.26. The RSI (14-day) is at 59.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $341.42 implies 19.3% upside from current levels. Volatility is low at 17.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for The Cigna Group (CI): The trailing P/E ratio is 11.96, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 8.24, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.83, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.77. Price-to-Sales is 0.27. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering CI, the consensus price target is $341.42. This represents a 19.3% upside from the current price of $286.26. The range spans from a low target of $290.00 to a high target of $400.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, The Cigna Group (CI) pays a dividend with a current yield of approximately 2.18%. The annualized dividend rate is $6.14 per share. The payout ratio is 25.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-09-08T00:00:00.000Z.
Key risks for The Cigna Group (CI) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is The Cigna Group's (CI) current debt and financial health profile: Total debt stands at $31.88B. The debt-to-equity ratio is 74.29, which is moderate and generally manageable for most companies. The current ratio is 0.85, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.69. The company holds $7.26B in cash and equivalents. Free cash flow is positive at $7.98B, providing a cushion for debt servicing and shareholder returns.